| General Information of Drug Metabolite (DM) (ID: DM019544) |
| DM Name |
PF-04965842 Metabolites M2
|
| Structure |
|
|
3D MOL is unavailable
|
2D MOL is unavailable
|
|
|
|
|
|
|
|
| Full List of Drug-Metabolizing Enzyme (DME) Related to This DM |
| DME(s) Producing This DM through Metabolism |
| DME Name |
DME ID |
Reactant |
Reaction |
Related Drug |
REF |
|
Cytochrome P450 2C9 (CYP2C9)
|
DME0019
|
| Unclear - Unclear |
PF-04965842
|
[1] |
|
Mephenytoin 4-hydroxylase (CYP2C19)
|
DME0021
|
| Unclear - Unclear |
PF-04965842
|
[1] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Full List of Drug(s) That Produce This DM By Metabolism |
| PF-04965842 |
DR3486
|
Phase 3 |
Atopic dermatitis |
|
|
| References |
| 1 |
Safety, pharmacokinetics and pharmacodynamics of four-hour intravenous infusions of eritoran in healthy Japanese and Caucasian men
|
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.
